Bipolar Disorders: Bipolar 1, Bipolar 2, and Cyclothymic Disorder

2017 ◽  
pp. 83-120
Author(s):  
Thomas L. Schwartz
Author(s):  
Marco Del Giudice

The chapter discusses disorders in the bipolar spectrum. Bipolar disorders (BDs) and cyclothymic disorder are marked by mania, a state of abnormally high energy and activity coupled with persistently elevated, expansive, or irritable mood. After an overview of these disorders, their developmental features, and the main risk factors identified in the epidemiological literature, the chapter critically reviews existing evolutionary models and suggests new directions for research. The final section applies the criteria developed earlier in the book to classify the disorders within the fast-slow-defense (FSD) model and identify functionally distinct subtypes. The author proposes to tentatively distinguish between two subtypes of BDs: a high-frequency fast spectrum subtype (F-BD) with strong links to schizophrenia and a low-frequency slow spectrum subtype (S-BD) marked by higher comorbidity with autism.


2019 ◽  
Vol 26 (38) ◽  
pp. 6942-6969 ◽  
Author(s):  
Federico Mucci ◽  
Maria Teresa Avella ◽  
Donatella Marazziti

Background: Attention deficit hyperactivity (ADHD) disorder is a neurodevelopmental disorder characterized by inattention, hyperactivity, disruptive behaviour, and impulsivity. Despite considered typical of children for a long time, the persistence of ADHD symptoms in adulthood gained increasing interest during the last decades. Indeed, its diagnosis, albeit controversial, is rarely carried out even because ADHD is often comorbid with several other psychiatric diosrders, in particular with bipolar disorders (BDs), a condition that complicates the clinical picture, assessment and treatment. Aims: The aim of this paper was to systematically review the scientific literature on the neurobiological, clinical features and current pharmacological management of ADHD comorbid with BDs across the entire lifespan, with a major focus on the adulthood. Discussion: The pharmacology of ADHD-BD in adults is still empirical and influenced by the individual experience of the clinicians. Stimulants are endowed of a prompt efficacy and safety, whilst non-stimulants are useful when a substance abuse history is detected, although they require some weeks in order to be fully effective. In any case, an in-depth diagnostic and clinical evaluation of the single individual is mandatory. Conclusions: The comorbidity of ADHD with BD is still a controversial matter, as it is the notion of adult ADHD as a distinct nosological category. Indeed, some findings highlighted the presence of common neurobiological mechanisms and overlapping clinical features, although disagreement does exist. In any case, while expecting to disentangle this crucial question, a correct management of this comorbidity is essential, which requires the co-administration of mood stabilizers. Further controlled clinical studies in large samples of adult ADHD-BD patients appear extremely urgent in order to better define possible therapeutic guidelines, as well as alternative approaches for this potentially invalidating condition.


2015 ◽  
Vol 21 (23) ◽  
pp. 3352-3358 ◽  
Author(s):  
Pierre Geoffroy ◽  
Bruno Etain ◽  
Jean-Arthur Franchi ◽  
Frank Bellivier ◽  
Philipp Ritter
Keyword(s):  

2013 ◽  
Vol 13 (18) ◽  
pp. 2364-2385 ◽  
Author(s):  
J. Bumb ◽  
F. Enning ◽  
F. Leweke

Sign in / Sign up

Export Citation Format

Share Document